Amgen to Establish New Science and Innovation Centre in Hyderabad’s Genome Valley

Global biopharmaceutical giant Amgen is doubling down on its commitment to India, announcing plans to open a state-of-the-art Science and Innovation Centre in Hyderabad’s premier Genome Valley. Slated to become operational in 2027, this new facility will mark a significant expansion of Amgen’s global research and development (R&D) network, which currently comprises seven research laboratories worldwide.

Bridging Wet-Lab Science and Digital Innovation

The new Hyderabad centre is designed to be a powerhouse of discovery. It will focus on critical, high-impact areas including:

• Discovery Chemistry
• Drug Metabolism and Pharmacokinetics (DMPK)
• Precision Medicine
• Data Science and Digital Technologies

By integrating experimental “wet-lab” science with advanced data analytics and AI-driven tools, the centre aims to dramatically accelerate the discovery and development of life-saving medicines. This facility will seamlessly complement Amgen’s existing Global Capability Centre (GCC) in Hyderabad, creating a powerful synergy between digital innovation and hands-on biological research.

Why Hyderabad? A Thriving Life Sciences Ecosystem

Hyderabad has long been recognized as India’s “Genome Valley,” but this new investment signals a shift from manufacturing and clinical research to high-value, early-stage discovery.

D. Sridhar Babu, Telangana’s Minister for IT and Industries, praised the decision, highlighting the state’s robust ecosystem: “Hyderabad brings together scientific talent, technology, and industry at scale and has built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines. The next chapter is about taking that strength into discovery and innovation. Our ambition is to make Hyderabad a place where the next generation of medicines and therapies can be discovered, developed, and taken to the world.”

Leadership Perspectives on Global Integration

For Amgen, this move is about creating a truly interconnected global R&D footprint.

Jay Bradner, Executive Vice President of Research and Development, Artificial Intelligence, and Data at Amgen, noted that the Genome Valley centre will perfectly complement the company’s strong US-based R&D operations. It will expand Amgen’s ability to connect science, data, and technology across its global research system, translating complex insights into tangible new medicines.

Som Chattopadhyay, Senior Vice President of Global Business Solutions and National Executive at Amgen, emphasized that this development firmly establishes India as a critical, strategic pillar in Amgen’s global R&D network.

Echoing this sentiment, Naveen Gullapalli, Managing Director of Amgen India, highlighted the region’s human capital: “Hyderabad’s STEM talent and life sciences ecosystem will support advanced technologies at scale. Our new centre at Genome Valley will help integrate biotechnology and digital innovation to serve more patients globally.”

Looking Ahead

Amgen’s investment in Hyderabad is a resounding vote of confidence in India’s scientific prowess and its potential to drive global healthcare innovation. As the centre gears up for its 2027 launch, it promises to create high-value jobs, foster cutting-edge research, and cement Hyderabad’s status as a premier global destination for biotech discovery and digital health innovation.

The future of medicine is being written in Hyderabad, and Amgen is ready to lead the next chapter.